HC Wainwright Has Strong Forecast for MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Monopar Therapeutics in a report released on Wednesday, January 22nd. HC Wainwright analyst S. Lee now anticipates that the company will earn $0.70 per share for the year, up from their prior forecast of $0.12. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09.

Several other research analysts also recently commented on the company. Piper Sandler started coverage on Monopar Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price target on the stock. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $39.32 on Friday. The business’s 50-day simple moving average is $24.19 and its 200-day simple moving average is $12.34. Monopar Therapeutics has a 52 week low of $1.54 and a 52 week high of $39.99. The firm has a market capitalization of $239.85 million, a PE ratio of -19.96 and a beta of 1.23.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was bought at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the purchase, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.